These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11750381)

  • 1. Rapamycin reduces rejection in heart transplant recipients.
    Radovancevic B; El-Sabrout R; Thomas C; Radovancevic R; Frazier OH; Van Buren C
    Transplant Proc; 2001; 33(7-8):3221-2. PubMed ID: 11750381
    [No Abstract]   [Full Text] [Related]  

  • 2. Mycophenolate mofetil reduces anti-HLA antibody production and cellular rejection in heart transplant recipients.
    Lietz K; John R; Schuster M; Ankersmit J; Burke E; Suciu-Foca N; Edwards N; Mancini D; Itescu S
    Transplant Proc; 2002 Aug; 34(5):1828-9. PubMed ID: 12176593
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of rapamycin, RS 61443, cyclosporine, and low-dose heparin as treatment for transplant vasculopathy in a rat model of chronic allograft rejection.
    Schmid C; Heemann U; Azuma H; Tilney NL
    Transplant Proc; 1995 Feb; 27(1):438-9. PubMed ID: 7879053
    [No Abstract]   [Full Text] [Related]  

  • 4. Sirolimus (rapamycin) potentiates cyclosporine in prevention of acute lung rejection.
    Longoria J; Roberts RF; Marboe CC; Stouch BC; Starnes VA; Barr ML
    J Thorac Cardiovasc Surg; 1999 Apr; 117(4):714-8. PubMed ID: 10096966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study of steroid withdrawal from kidney transplant recipients on sirolimus-cyclosporine a combination therapy.
    Mahalati K; Kahan BD
    Transplant Proc; 2001; 33(7-8):3232-3. PubMed ID: 11750385
    [No Abstract]   [Full Text] [Related]  

  • 6. Synergistic interaction of FTY720 with cyclosporine or sirolimus to prolong heart allograft survival.
    Stepkowski SM; Wang M; Qu X; Yu J; Okamoto M; Tejpal N; Kahan BD
    Transplant Proc; 1998 Aug; 30(5):2214-6. PubMed ID: 9723445
    [No Abstract]   [Full Text] [Related]  

  • 7. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis.
    Zucker MJ; Baran DA; Arroyo LH; Goldstein DJ; Neacy C; Mele L; Weinberg AD; Prendergast TW; Ribner HS
    Transplant Proc; 2005 Jun; 37(5):2231-9. PubMed ID: 15964386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of sirolimus in combination with low-dose cyclosporine and steroids on acute renal allograft rejection.
    Tsai MK; Chueh SC; Hu RH; Lee PH
    J Formos Med Assoc; 2003 Feb; 102(2):91-6. PubMed ID: 12709737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rescue therapy with rapamycin blocks an ongoing process of heart allograft rejection.
    Ferraresso M; Wang ME; Stepkowski SM; Kahan BD
    Transplant Proc; 1993 Feb; 25(1 Pt 1):729. PubMed ID: 8438460
    [No Abstract]   [Full Text] [Related]  

  • 10. Sirolimus therapy in cardiac transplantation.
    Radovancevic B; Vrtovec B
    Transplant Proc; 2003 May; 35(3 Suppl):171S-176S. PubMed ID: 12742492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin and cyclosporine A treatment: a novel regimen to prevent chronic allograft rejection in sensitized hosts.
    Wasowska B; Hancock WW; Onodera K; Korom S; Stadlbauer TH; Zheng XX; Strom TB; Kupiec-Weglinski JW
    Transplant Proc; 1997; 29(1-2):333. PubMed ID: 9123026
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of cyclosporine A monotherapy on the incidence of rejection and infection episodes in heart transplant patients.
    Seydoux C; Stumpe F; Hurni M; Ruchat P; Fischer A; Mueller X; von Segesser L; Goy JJ
    Transplant Proc; 1998 Dec; 30(8):4037-43. PubMed ID: 9865288
    [No Abstract]   [Full Text] [Related]  

  • 13. Rapamycin for cardiac transplant rejection and vasculopathy: one stone, two birds?
    Edelman ER; Danenberg HD
    Circulation; 2003 Jul; 108(1):6-8. PubMed ID: 12847052
    [No Abstract]   [Full Text] [Related]  

  • 14. Sirolimus antirejection therapy for renal transplantation with cyclosporine-based immunosuppression: case reports.
    Tsai MK; Hu RH; Lee PH
    Transplant Proc; 2003 Feb; 35(1):219-20. PubMed ID: 12591371
    [No Abstract]   [Full Text] [Related]  

  • 15. Emerging strategies for the clinical application of rapamycin.
    Kahan BD
    Clin Biochem; 1998 Jul; 31(5):341-4. PubMed ID: 9721432
    [No Abstract]   [Full Text] [Related]  

  • 16. Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study.
    Potena L; Prestinenzi P; Bianchi IG; Masetti M; Romani P; Magnani G; Fallani F; Coccolo F; Russo A; Ponticelli C; Rapezzi C; Grigioni F; Branzi A
    J Heart Lung Transplant; 2012 Jun; 31(6):565-70. PubMed ID: 22341702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
    Gonwa TA; Hricik DE; Brinker K; Grinyo JM; Schena FP;
    Transplantation; 2002 Dec; 74(11):1560-7. PubMed ID: 12490789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of humoral rejection in heart transplant recipients treated with tacrolimus or cyclosporine A.
    Behr TM; Richter K; Fischer P; Spes CH; Meiser B; Reichart B; Pongratz D; Feucht H; Theisen K; Angermann CE
    Transplant Proc; 1998 Aug; 30(5):1920-1. PubMed ID: 9723333
    [No Abstract]   [Full Text] [Related]  

  • 19. Progressive change in tolerance mechanisms after withdrawing combination immunosuppression with cyclosporine and rapamycine or leflunomide.
    Lin Y; Waer M
    Transplant Proc; 1996 Dec; 28(6):3159. PubMed ID: 8962224
    [No Abstract]   [Full Text] [Related]  

  • 20. Sirolimus rescue therapy for refractory rejection in renal transplant recipients.
    Hong JC; Kahan BD
    Transplant Proc; 2001; 33(1-2):1033. PubMed ID: 11267178
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.